Table 1 Baseline characteristics of study population.
Variables | Combination therapy (n = 70) | Tegoprazan monotherapy (n = 71) | P value |
|---|---|---|---|
Age (mean ± SD) | 63.8 ± 9.0 | 65.42 ± 9.75 | 0.31 |
Sex (male), n (%) | 42 (60.0%) | 49 (69.0%) | 0.29 |
BMI (mean ± SD) | 25.25 ± 3.34 | 25.15 ± 3.19 | 0.85 |
Underlying disease, n (%) | |||
Diabetes | 8 (11.4%) | 12 (16.9%) | 0.47 |
Hypertension | 30 (42.9%) | 33 (46.5%) | 0.74 |
Pre-ESD histology, n (%) | 0.39 | ||
Adenoma | 59 (84.3%) | 55 (77.5%) | |
Carcinoma | 11 (15.7%) | 16 (22.5%) | |
Post-ESD histology, n (%) | 0.78 | ||
Adenoma | 48 (68.6%) | 45 (63.4%) | |
Carcinoma | 20 (28.6%) | 23 (32.4%) | |
No dysplasia | 2 (2.9%) | 3 (4.2%) | |
Location, n (%) | 0.92 | ||
Upper body | 9 (12.9%) | 9 (12.7%) | |
Lower body | 12 (17.1%) | 14 (19.7%) | |
Angle | 8 (11.4%) | 10 (14.1%) | |
Antrum | 41 (58.6%) | 38 (53.5%) | |
Tumor with fibrosis, n (%) | 5 (7.1%) | 7 (9.9%) | 0.76 |
Long diameter of tumor (mm) (mean ± SD) | 13.7 ± 7.75 | 12.58 ± 8.36 | 0.41 |
Specimen size after fixation (mm2) (mean ± SD) | 1073.6 ± 543.19 | 1019.76 ± 1035.84 | 0.70 |
En bloc resection rate, n (%) | 70 (100%) | 71 (100%) | NA |
Complete resection rate, n (%) | 69 (98.6%) | 70 (98.6%) | > 0.999 |
Submucosal invasion, n (%) | 1/20 (5.0%) | 5/23 (21.7%) | 0.19 |
Procedure time (min) (mean ± SD) | 29.95 ± 24.22 | 30.35 ± 20.60 | 0.92 |
Baseline KGSRS score (mean ± SD) | 1.79 ± 2.84 | 1.97 ± 2.90 | 0.70 |
Helicobacter pylori infection, n (%) | 29 (41.4%) | 26 (36.6%) | 0.37 |
